Abstract
Purpose :
To assess the efficacy and safety of ranibizumab in patients with vision loss secondary to diabetic macular edema (DME).
Methods :
Retrospective analysis of consecutive patients with vision loss due to DME and treated with ranibizumab. All patients received a loading dose of 3 monthly injections followed by re-treatments on an as needed basis. Primary endpoint was the change in best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints were the change in central retinal thickness (CRT) and number of intravitreal injections (IVI) at 12 months.
Results :
One hundred and six eyes of 78 patients were included. BCVA changed from 48.3 letters at baseline to 59 letters at 12 months (p <0.0001) (mean gain: +10.7 letters) and 38% of patients had a final BCVA >70 letters. CRT decreased from 519 μm at baseline to 355 μm at 12 months (p <0.0001). The threshold of the first quartile of the baseline VA was 40 letters. Patients with a baseline VA >40 letters had a higher final VA of 66 ± 14 letters vs 43 ± 18 letters for patients with a baseline VA ≤40 letters (p <0.0001). A mean number of 5.4 (3-10) IVI were administered.
Conclusions :
This study conducted in a clinical setting confirms the results of previous randomized trials. The final BCVA was mainly impacted by the baseline BCVA, which supports the early treatment of DME before patients experience a severe vision loss.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.